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Abstract: Recently, a blaNDM-9 and mcr-1 co-harboring E. coli ST 617 isolate was identified from an
asymptomatic carrier in Korea. An 81-year-old female was admitted to a university hospital for aortic
cardiac valve repair surgery. Following surgery, she was admitted to the intensive care unit (ICU) for
three days, and carbapenem-resistant E. coli YMC/2017/02/MS631 was isolated from a surveillance
culture (rectal swab). Antimicrobial susceptibility testing (AST) for colistin was not performed
at that time. Upon retrospective study, further AST revealed resistance to all tested antibiotics,
including meropenem, imipenem, ceftazidime-avibactam, amikacin, gentamicin, ciprofloxacin,
trimethoprim-sulfamethoxazole, and colistin, with the exception of tigecycline. Whole genome
sequencing analyses showed that this strain belonged to the ST617 serotype O89/162: H10 and
harbored three β-lactamase genes (blaTEM-1B, blaCTX-M-55, blaNDM-9), mcr-1, and 14 other resistance
genes. Seven plasmid replicon types (IncB, IncFII, IncI2, IncN, IncY, IncR, IncX1) were identified.
Horizontal transfer of blaNDM-9 and mcr-1 from donor cells to the recipient E. coli J53 has been
observed. blaNDM-9 and mcr-1 were carried by IncB and IncI2 plasmids, respectively. To speculate on
the incidence of this strain, routine rectal swab screening to identify asymptomatic carriers might be
warranted, in addition to the screening of ICU patients.
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1. Introduction
Since the first New Delhi metallo-β-lactamase 1 (blaNDM-1) was identified from a carbapenem-resistant
Klebsiella pneumoniae strain [1], several variations of this metallo-β-lactamase have been discovered all
over the world. One variant, blaNDM-9, was identified from a K. pneumoniae clinical isolate in China [2].
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Accompanying the rise of carbapenem-resistant bacteria, colistin has become used more commonly,
despite its serious side effects. Under the selective pressure of colistin, the first blaNDM-9 and mcr-1
co-harboring E. coli ST167 strain was identified from a retail chicken in 2016 [3]. Subsequent thereto,
E. coli strains co-harboring blaNDM-9 and mcr-1 were reported from a chicken farm in China [4]. Since
then, there have been concerns over the spread of this strain to humans. A blaNDM-9 and mcr-1
co-harboring E. coli 5CRE51 strain from a urine sample was first reported in Taiwan in 2017 [5].
This strain carried two different plasmids that harbored blaNDM-9 and mcr-1 and belonged to the
ST617 strain [6]. Recently, a blaNDM-9 and mcr-1 co-harboring E. coli isolate was identified from
an asymptomatic carrier in Korea in a retrospective study. Subsequent thereto, phenotypic and
phylogenomic analyses were conducted to trace the strain’s origin.
2. Case Report
An 81-year-old female was admitted to a university hospital in February 2017 for aortic cardiac
valve repair surgery. The patient had chest pain and dyspnea on exertion that had been aggravated
six months before a diagnosis of severe aortic regurgitation. The patient had no history of abroad
travel, visiting a farm or any signs of infections. She received preoperative antibiotic prophylaxis
with amoxicillin-clavulanate. Following surgery, she was admitted to the intensive care unit (ICU)
for three days, and carbapenem-resistant E. coli YMC/2017/02/MS631 was isolated from a rectal swab
surveillance culture, which was routinely performed to stop the spreading of Klebsiella pneumoniae
carbapenemase-producing Enterobacteriaceae in the ICU. Antimicrobial susceptibility testing (AST)
for colistin was not performed at that time. Upon retrospective study, colistin resistance was detected:
In vitro AST was performed using both broth microdilution and agar dilution methods. The results
were interpreted according to the Clinical and Laboratory Standards Institute guidelines [7], with the
exception of tigecycline and colistin, for which the European Committee on Antimicrobial Susceptibility
Testing v9.0 was applied (http://www.eucast.org/clinical_breakpoints/). The isolate was resistant to
all tested antibiotics (amoxicillin-clavulanic acid, piperacillin, piperacillin-tazobactam, cefotaxime,
ceftazidime, cefepime, cefoxitin, aztreonam, ertapenem, meropenem, imipenem, ceftazidime-avibactam,
amikacin, gentamicin, ciprofloxacin, trimethoprim-sulfamethoxazole, and colistin), except for
tigecycline (Table 1).
Whole genomic DNA was extracted and sequenced using an Illumina Hiseq2500TM (Illumina,
Valencia, CA, USA). Sequence reads were assembled using SPAdes version 3.12 [8]. The genome was
annotated employing Rapid Annotation using Subsystem Technology [9] and deposited in the NCBI
GenBank with the accession number SBHK00000000. Resistance genes, serotype, multi-locus sequence
type (MLST), plasmid replicon type, and virulence factors were analyzed using ResFinder 3.1 [10],
SeroTypeFinder 2.0 [11], MLST 2.0 [12], PlasmidFinder 2.0 [13], and VirulenceFinder 2.0 [14], respectively.
Despite sharing the same sequence type (ST617) and serotype (O89/162: H10) with E. coli 5CRE51 [6],
this strain carried additional resistance genes, namely, blaTEM-1B, blaCTX-M-55, aph(3’)IIa, aph(3’)Ib,
rmtB, aph(6)-Id, oqxA, oqxB, mph(A), mdf(A), and sul2, accounting for cephalosporin, aminoglycoside,
fluoroquinolone, macrolide, and sulfamethoxazole resistance (Table 1). Additionally, the mcr-1 sequence
from E. coli YMC/2017/02/MS631 had one silent mutation at position 1074 (C→A), compared with a
previously reported mcr-1. Seven plasmid replicon types (IncB, IncFII, IncI2, IncN, IncY, IncR, IncX1),
and two virulence factors (gad, iss) were identified. Transferability of the blaNDM-9 and mcr-1 genes was
achieved by conjugation experiments with E. coli J53 as the recipient strain [15,16]. Transconjugants
were selected on Mueller–Hinton agar plates containing 100 µg/mL of sodium azide with 4 µg/mL of
imipenem or 2 µg/mL of colistin. Resistance genes and plasmid replicon types in the transconjugants
were identified by PCR and Sanger sequencing using designed primers (Table S1). The transconjugant
E. coli EJ533 was susceptible to all tested antibiotics but colistin and harbored mcr-1 on the IncI2
type plasmid. Meanwhile, the transconjugant E. coli EJ5331 was resistant against all β-lactams but
aztreonam and carried blaNDM-9 and other resistance genes (aadA2, fosA3, mph(A), sul2, and dfrA12) on
the IncB type plasmid (Table 1).
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Selected by Colistin Selected by Imipenem E. coli J53
E. coli EJ533 E. coli EJ5331
Source Asymptomatic carrier - - -





aph(6)-Id, aadA2, oqxA, oqxB,
fosA3, mph(A), mdf(A),floR,






MLST 617 - - -
Serotype O89/162:H10 - - -
Plasmid replicon type(s) IncB, IncFII, IncI2, IncN,IncY, IncR, IncX1 IncI2 IncB -
Virulence factors gad, iss
ompC, ompF Intact
MIC (µg/mL, interpretation)
Amoxicillin-clavulanic acid 128, R † 4, S ‡ 8, R ‡ 4, S ‡
Piperacillin ≥256, R † N/D N/D N/D
Piperacillin-tazobactam ≥256, R † ≤4, S ‡ ≥128, R‡ ≤4, S ‡
Cefotaxime ≥256, R † ≤1, S ‡ ≥64, R ‡ ≤1, S ‡
Ceftazidime ≥256, R † ≤1, S ‡ ≥64, R ‡ ≤1, S ‡
Cefepime ≥256, R † ≤1, S ‡ ≥64, R ‡ ≤1, S ‡
Cefoxitin ≥256, R † 8, S ‡ 32, R § ≤1, S ‡
Aztreonam ≥128, R † ≤1, S ‡ ≤1, S ‡ ≤1, S ‡
Ertapenem 64, R † ≤0.5, S ‡ 4, R ‡ ≤0.5, S ‡
Meropenem 16, R † N/D N/D N/D
Imipenem 32, R † ≤0.25, S ‡ 8, R ‡ ≤0.25, S ‡
Ceftazidime-avibactam ≥256, R † N/D N/D N/D
Colistin 4, R ‡ 4, R ‡ ≤0.125, S ‡ <0.125, S ‡
Amikacin ≥16, R ‡ ≤2, S ‡ ≤2, S ‡ ≤2, S ‡
Gentamicin ≥16, R ‡ ≤1, S ‡ ≤1, S ‡ ≤1, S ‡
Ciprofloxacin ≥4, R ‡ ≤0.25, S ‡ ≤0.25, S ‡ ≤0.25, S ‡
Tigecycline 0.5, S ‡ ≤0.5, S ‡ ≤0.5, S ‡ ≤0.5, S ‡
Trimethoprim-sulfamethoxazole 320, R ‡ ≤20, S ‡ ≤20, S ‡ ≤20, S ‡
Abbreviations: MIC, minimal inhibitory concentration; MLST, Multi Locus Sequence Type; N/D, not determined.
In vitro antimicrobial susceptibility testing was performed using an agar dilution method † and a broth microdilution
method ‡ following the Clinical and Laboratory Standards Institute (CLSI) guidelines M100 28th ed. MIC interpretations
followed CLSI M100 28th ed, with the exception of tigecycline and colistin, for which the European Committee on
Antimicrobial Susceptibility Testing guidelines v9.0 were applied.
The relatedness of E. coli 5CRE51 and YMC/2017/02/MS631 in the context of worldwide E. coli
ST617 distribution was investigated using EnteroBase database (http://enterobase.warnick.ac.uk/)
(Figure 1). Altogether, 200 E. coli ST617 strains among 82,737 E. coli genomes (0.24%) have been reported
in EnteroBase with the key words “E. coli” and “ST617” at the time of writing this paper (File S1).
E. coli ST617 strains have been detected in at least 31 countries and from different sources, including
human, animal, and environmental samples (Figure S1, S2A). Among them, 170 E. coli genomes were
accessible for analysis (File S1). Thirteen different serotypes were identified from the collected genomes.
Considering 170 genomes, 82 (48.2%) belonged to serotype O89/162: H10 (Figure S2B) and were
included in the phylogenomic tree constructed using CSI phylogeny 1.4 [17]. The phylogenetic tree was
visualized using iTOL (https://itol.embl.de/) and indicated that E. coli YMC/2017/02/MS631 was distant
from E. coli 5CRE51 and other strains. The closest strains were detected in Poland (ESC_IA1353AA)
and Germany (ESC_IA2276AA) (Figure 1). Meanwhile, E. coli 5CRE51 belonged to a clade with strains
collected from Oman (ESC_EA6169AA) and The Netherlands (ESC_EA9479AA). This suggested that
the two strains emerged independently.
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Figure 1. Phylogenomic comparison of the 82 E. coli ST617 strains collected from EnteroBase (http:
//enterobase.warnick.ac.uk/). The phylogenetic tree was constructed using CSI phylogeny 1.4 (https:
//cge.cbs.dtu.dk/services) with the standard parameters. iTOL (https://itol.embl.de/) was used to
visualize the phylogenetic tree. The strain ESC_BA5832AA was selected as the reference strain. Origin,
source and collection year of the isolates also were illustrated. The red box indicates the E. coli
YMC/2017/02/MS631, which is closely related to the strain ESC_IA1353AA isolated from Poland in 2014.
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3. Discussion
The first blaNDM-9 and mcr-1 co-harboring E. coli isolate belonged to a ST167 strain was followed
by ST10 complexes, ST101, ST156, and ST297 [3,4]. The primary source was chicken meat. This
strain rarely has been reported in clinical settings. Our report is important because it was detected
coincidentally in a retrospective cohort study, and the strain displayed high antibiotic resistance with
complicated plasmid types. Additionally, this strain displayed a broader resistance spectrum than the
E. coli 5CRE51 isolate from Taiwan. Furthermore, the strain had two- and eight-folds higher minimal
inhibitory concentrations (MICs) for meropenem and imipenem and an eight-fold higher MIC for
amikacin in comparison with E. coli 5CRE51. However, the colistin MIC was the same: 4 µg/mL [5].
Resistome profiles, plasmid typing, and whole-genome phylogenetic tree analyses suggested that the
two strains were not closely related. Interestingly, E. coli ST617 has mainly been detected in European
countries, the United States, and China, and only two isolates of E. coli ST617 have been reported for
Taiwan and Korea, according to EnteroBase (Figure S2A). The dominance of E. coli ST617 serotype
O89/162:H10 among 13 serotypes may suggest that E. coli ST617 serotype O89/162: H10 can be a
potential reservoir for blaNDM-9 and mcr-1 co-harboring E. coli in clinical settings.
According to the EUCIC medical guidelines on decolonization [18], there is a lack of evidence
regarding the efficiency of decolonization for multidrug-resistant gram-negative organisms in
hospitalized patients. Hence, the patient can be discharged without any treatment or intervention for
decolonization. This may, in turn, lead to a silent continuous spread of this strain in the population
at large. Additionally, travel by asymptomatic blaNDM-9 and mcr-1 carriers could facilitate strain
transmission. A recent study emphasized the contribution of fecal pollution to an abundance of
resistance genes in effluent-receiving environments [19]. Routine rectal swab screening to identify
asymptomatic colistin and/or carbapenem-resistance carriers might be warranted to control the spread
of multi-drug resistant organisms in hospital settings.
4. Conclusions
To the best of our knowledge, this is the first report of resistome profiles, plasmid typing,
and whole-genome phylogenetic tree analyses of a blaNDM-9 and mcr-1 co-harboring E. coli strain isolated
from an asymptomatic carrier. Moreover, the resistance genes were transferable to azide-resistant
E. coli J53. Further surveillance studies should be conducted to detect the prevalence of this strain
among health-care systems in Korea.
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